EB-PSMA-617

EB-PSMA-617 is an advanced version of PSMA-617, designed to enhance pharmacokinetic properties through conjugation with Evans Blue (EB), thereby extending its circulation half-life for improved prostate tumor targeting and radiotherapy effectiveness. In preclinical studies with PC3-PIP-loaded mice, EB-PSMA-617 showed an extended blood half-life, greater accumulation in PSMA-positive tumors, and effective tumor elimination with reduced radioactivity.

S(=O)(=O)(O)C=1C2=C(C(O)=C(N=NC3=C(C)C=C(C=C3)C4=CC(C)=C(NC([C@@H](NC(CN5CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC5)=O)CCCCNC(CCN6C(=O)C(SCC(NC[C@@H]7CC[C@@H](C(N[C@H](CC8=CC9=C(C=C8)C=CC=C9)C(NCCCC[C@H](NC(N[C@@H](CCC(O)=O)C(O)=O)=O)C(O)=O)=O)=O)CC7)=O)CC6=O)=O)=O)C=C4)C=C2)C(N)=C(S(=O)(=O)O)C1